{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:16:50Z","timestamp":1793049410321,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Initiative SMA \u2013 Gemeinsam f\u00fcr eine Therapie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11136-024-03665-5","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:02:31Z","timestamp":1715846551000},"page":"1949-1959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-7151","authenticated-orcid":false,"given":"Erik","family":"Landfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenike","family":"Leibrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Hussong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie C.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zemlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Dillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Flotats-Bastardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"9630","key":"3665_CR1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn, M. R., & Wang, C. H. (2008). Spinal muscular atrophy. Lancet, 371(9630), 2120\u20132133.","journal-title":"Lancet"},{"issue":"1","key":"3665_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill, K., Schwartz, O., Blaschek, A., et al. (2021). Newborn screening for spinal muscular atrophy in Germany: Clinical results after 2 years. Orphanet Journal of Rare Diseases, 16(1), 153.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"18","key":"3665_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., et al. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine, 377(18), 1723\u20131732.","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"3665_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., et al. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine, 377(18), 1713\u20131722.","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"3665_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello, G., Darras, B. T., Day, J. W., Deconinck, N., Klein, A., Masson, R., et al. (2021). Risdiplam in Type 1 spinal muscular atrophy. New England Journal of Medicine, 384(10), 915\u2013923.","journal-title":"New England Journal of Medicine"},{"issue":"5\u20136","key":"3665_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat, T. L., & Davies, K. E. (1992). International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscular Disorders, 2(5\u20136), 423\u2013428.","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"3665_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone, V. A., Walter, M. C., Attarian, S., Delstanche, S., Mercuri, E., Lochm\u00fcller, H., et al. (2020). Measuring outcomes in adults with spinal muscular atrophy - challenges and future directions - meeting report. Journal of Neuromuscular Diseases, 7(4), 523\u2013534.","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"2","key":"3665_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., et al. (2018). Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 28(2), 103\u2013115.","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"3665_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel, R. S., Mercuri, E., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., et al. (2018). Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 28(3), 197\u2013207.","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"3665_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-023-02639-z","volume":"18","author":"B Leibrock","year":"2023","unstructured":"Leibrock, B., Landfeldt, E., Hussong, J., Huelle, T., Mattheus, H., Thiele, S., et al. (2023). Areas of improvement in the medical care of SMA: Evidence from a nationwide patient registry in Germany. Orphanet Journal of Rare Diseases, 18(1), 32.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"12","key":"3665_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2165\/00019053-200624120-00005","volume":"24","author":"U Ravens-Sieberer","year":"2006","unstructured":"Ravens-Sieberer, U., Erhart, M., Wille, N., Wetzel, R., Nickel, J., & Bullinger, M. (2006). Generic health-related quality-of-life assessment in children and adolescents: Methodological considerations. PharmacoEconomics, 24(12), 1199\u20131220.","journal-title":"PharmacoEconomics"},{"issue":"2","key":"3665_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jpepsy\/21.2.175","volume":"21","author":"LE Spieth","year":"1996","unstructured":"Spieth, L. E., & Harris, C. V. (1996). Assessment of health-related quality of life in children and adolescents: An integrative review. Journal of Pediatric Psychology, 21(2), 175\u2013193.","journal-title":"Journal of Pediatric Psychology"},{"issue":"4","key":"3665_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40258-020-00624-2","volume":"19","author":"E Landfeldt","year":"2021","unstructured":"Landfeldt, E., Pechmann, A., McMillan, H. J., Lochm\u00fcller, H., & Sejersen, T. (2021). Costs of illness of spinal muscular atrophy: A systematic review. Applied Health Economics and Health Policy, 19(4), 501\u2013520.","journal-title":"Applied Health Economics and Health Policy"},{"issue":"3","key":"3665_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","volume":"23","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt, E., Edstr\u00f6m, J., Sejersen, T., Tulinius, M., Lochm\u00fcller, H., & Kirschner, J. (2019). Quality of life of patients with spinal muscular atrophy: A systematic review. European Journal of Paediatric Neurology, 23(3), 347\u2013356.","journal-title":"European Journal of Paediatric Neurology"},{"issue":"1","key":"3665_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/JND-230071","volume":"11","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt, E., Leibrock, B., Hussong, J., et al. (2024). Self-reported health-related quality of life of children with spinal muscular atrophy: Insights from a nationwide patient registry in Germany. Journal of Neuromuscular Diseases. 11(1), 117\u2013128.","journal-title":"Journal of Neuromuscular Diseases"},{"key":"3665_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727\u20131736.","journal-title":"Quality of Life Research"},{"key":"3665_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"J Horsman","year":"2003","unstructured":"Horsman, J., Furlong, W., Feeny, D., & Torrance, G. (2003). The health utilities index (HUI): Concepts, measurement properties and applications. Health and Quality of Life Outcomes, 1, 54.","journal-title":"Health and Quality of Life Outcomes"},{"key":"3665_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473\u2013483.","journal-title":"Medical Care"},{"issue":"6","key":"3665_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig, K., Graf von der Schulenburg, J. M., & Greiner, W. (2018). German Value Set for the EQ-5D-5L. PharmacoEconomics, 36(6), 663\u2013674.","journal-title":"PharmacoEconomics"},{"key":"3665_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","volume":"40","author":"DH Feeny","year":"2002","unstructured":"Feeny, D. H., Furlong, W. J., Torrance, G. W., et al. (2002). Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40, 113\u2013128.","journal-title":"Medical Care"},{"issue":"2","key":"3665_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271\u2013292.","journal-title":"Journal of Health Economics"},{"issue":"3","key":"3665_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1298\/ptr.E10201","volume":"25","author":"Y Uchio","year":"2022","unstructured":"Uchio, Y., Kajima, K., Suzuki, H., Nakamura, K., Saito, M., & Ikai, T. (2022). Pain in spinal muscular atrophy: a questionnaire study. Physical Therapy Research, 25(3), 150\u2013155.","journal-title":"Physical Therapy Research"},{"issue":"1","key":"3665_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s13023-021-02008-8","volume":"16","author":"M Yao","year":"2021","unstructured":"Yao, M., Xia, Y., Feng, Y., Ma, Y., Hong, Y., Zhang, Y., et al. (2021). Anxiety and depression in school-age patients with spinal muscular atrophy: A cross-sectional study. Orphanet Journal of Rare Diseases, 16(1), 385.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"12","key":"3665_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.626787","volume":"29","author":"L Mix","year":"2021","unstructured":"Mix, L., Winter, B., Wurster, C. D., Platen, S., Witzel, S., Uzelac, Z., Graf, H., Ludolph, A. C., & Lul\u00e9, D. (2021). Quality of life in SMA patients under treatment with nusinersen. Frontiers in Neurology, 29(12), 626787.","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"3665_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10198-019-01054-1","volume":"20","author":"T Grochtdreis","year":"2019","unstructured":"Grochtdreis, T., Dams, J., K\u00f6nig, H. H., & Konnopka, A. (2019). Health-related quality of life measured with the EQ-5D-5L: Estimation of normative index values based on a representative German population sample and value set. The European Journal of Health Economics, 20(6), 933\u2013944.","journal-title":"The European Journal of Health Economics"},{"issue":"7","key":"3665_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jval.2020.03.003","volume":"23","author":"EB Henry","year":"2020","unstructured":"Henry, E. B., Barry, L. E., Hobbins, A. P., McClure, N. S., & O\u2019Neill, C. (2020). Estimation of an instrument-defined minimally important difference in EQ-5D-5L index scores based on scoring algorithms derived using the EQ-VT version 2 valuation protocols. Value Health., 23(7), 936\u2013944.","journal-title":"Value Health."},{"issue":"4","key":"3665_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5040","volume":"5","author":"C Eiser","year":"2001","unstructured":"Eiser, C., & Morse, R. (2001). Quality-of-life measures in chronic diseases of childhood. Health Technology Assessment, 5(4), 1\u2013157.","journal-title":"Health Technology Assessment"},{"issue":"5","key":"3665_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/dmcn.12959","volume":"58","author":"R Pangalila","year":"2016","unstructured":"Pangalila, R. (2016). Quality of life in Duchenne muscular dystrophy: The disability paradox. Developmental Medicine and Child Neurology, 58(5), 435\u2013436.","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"1","key":"3665_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-017-0695-0","volume":"12","author":"J L\u00f3pez-Bastida","year":"2017","unstructured":"L\u00f3pez-Bastida, J., Pe\u00f1a-Longobardo, L. M., Aranda-Reneo, I., Tizzano, E., Sefton, M., & Oliva-Moreno, J. (2017). Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet Journal of Rare Diseases, 12(1), 141.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"446","key":"3665_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120545","volume":"15","author":"E Landfeldt","year":"2023","unstructured":"Landfeldt, E. (2023). Measuring health-related quality of life in duchenne muscular dystrophy: Current perspectives and recommendations. Journal of the Neurological Sciences, 15(446), 120545.","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"3665_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12955-023-02204-z","volume":"21","author":"RH Xu","year":"2023","unstructured":"Xu, R. H., Ma, B., Xin, H., Zhang, H., Zeng, Y., Luo, N., & Dong, D. (2023). Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy. Health and Quality of Life Outcomes, 21(1), 123.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"1","key":"3665_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/brainsci13010110","volume":"13","author":"C Wohnrade","year":"2023","unstructured":"Wohnrade, C., Velling, A. K., Mix, L., Wurster, C. D., Cordts, I., Stolte, B., et al. (2023). Health-related quality of life in spinal muscular atrophy patients and their caregivers-a prospective, cross-sectional, multi-center analysis. Brain Sciences, 13(1), 110.","journal-title":"Brain Sciences"},{"issue":"4","key":"3665_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JND-200610","volume":"8","author":"HJ McMillan","year":"2021","unstructured":"McMillan, H. J., Gerber, B., Cowling, T., Khuu, W., Mayer, M., Wu, J. W., et al. (2021). Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis., 8(4), 553\u2013568.","journal-title":"J Neuromuscul Dis."},{"key":"3665_CR34","unstructured":"Health Utilities Inc (HUInc). HUI Mark2 and Mark3 Reference Population Data. Available from: http:\/\/www.healthutilities.com\/ (Accessed July 15, 2023)."},{"issue":"1","key":"3665_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","volume":"15","author":"L Belter","year":"2020","unstructured":"Belter, L., Cruz, R., & Jarecki, J. (2020). Quality of life data for individuals affected by spinal muscular atrophy: A baseline dataset from the cure SMA community update survey. Orphanet Journal of Rare Diseases, 15(1), 217.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"3665_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/dmcn.15286","volume":"65","author":"T Dangouloff","year":"2023","unstructured":"Dangouloff, T., Hiligsmann, M., Deconinck, N., D\u2019Amico, A., Seferian, A. M., Boemer, F., & Servais, L. (2023). Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Developmental Medicine and Child Neurology, 65(1), 67\u201377.","journal-title":"Developmental Medicine and Child Neurology"},{"key":"3665_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00103-013-1700-y","volume":"56","author":"U Ellert","year":"2013","unstructured":"Ellert, U., & Kurth, B. M. (2013). Health-related quality of life in adults in Germany. Bundesgesundheitsbl, 56, 643\u2013649.","journal-title":"Bundesgesundheitsbl"},{"issue":"12","key":"3665_CR38","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/hec.1823","volume":"21","author":"B van den Berg","year":"2012","unstructured":"van den Berg, B. (2012). Sf-6d population norms. Health Economics, 21(12), 1508\u20131512.","journal-title":"Health Economics"},{"issue":"1","key":"3665_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7525-1-4","volume":"11","author":"SJ Walters","year":"2003","unstructured":"Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality of Life Outcomes, 11(1), 4.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"5","key":"3665_CR40","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/mus.25148","volume":"54","author":"ET Kruitwagen-Van Reenen","year":"2016","unstructured":"Kruitwagen-Van Reenen, E. T., Wadman, R. I., Visser-Meily, J. M., van den Berg, L. H., Schr\u00f6der, C., & van der Pol, W. L. (2016). Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle and Nerve, 54(5), 850\u2013855.","journal-title":"Muscle and Nerve"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03665-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03665-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03665-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T14:44:44Z","timestamp":1721400284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03665-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3665"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03665-5","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"8 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Marina Flotats-Bastardas has received consultant fees from Roche and Biogen. Dr Landfeldt is an employee of IQVIA, a contract research organization. Dr Maggie C. Walter has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche, Santhera, Sarepta, Pharnext, PTC Therapeutics, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Avexis, Biogen, PTC Therapeutics, Ultragenyx, Santhera, Sarepta, and worked as an ad-hoc consultant for AskBio, Audentes Therapeutics, Avexis, Biogen Pharma GmbH, Fulcrum Therapeutics, GLG Consult, Guidepoint Global, Gruenenthal Pharma, Novartis, Pharnext, PTC Therapeutics, Roche. Simone Thiele has received financial support for advisory services from PTC Therapeutics. The other authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}